Loading ...
The purpose of this study is to measure hair growth response to a new topical hairloss treatment called NEOSH101, created by Neosil inc.
The study is a Phase 2 Multi-center, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men.
What that means is that three equally sized treatment groups of 60 balding men will receive either topical NEOSH101 2.0%, minoxidil 5%, or a placebo. They will apply the treatments to their balding scalp twice daily for 16 weeks.
Their hair density, hair growth and hair diameter will all be measured using the TrichoScan method, which is a computerized system for measuring hair.
In addition to that physicians will assess their hair growth and also determine how well they were able to tolerate the medication.
The requirements to be eligible for the study are:
- Caucasian male
- Ages 18 - 49 Years
- Norwood/Hamilton class III-IV, with thinning hair in the vertex area
- Not currently using any other hair loss treatments
- Have not used minoxidil (Rogaine) for 6 months prior
- Have not used Finasteride (Propecia) for 12 months prior
- Have not used any other trial hair growth products for 6 months prior
The study is being conducted in Germany in February.
If you would like to apply contact Elisabeth Rowold, PhD tel: +49 40 606 897 34 email: elisabeth.rowold@bioskin.de
(No Ratings Yet)
Loading ...